Literature DB >> 18668131

Pathogenesis and progression of monoclonal gammopathy of undetermined significance.

J Bladé1, L Rosiñol, M T Cibeira, C F de Larrea.   

Abstract

In Caucasians, monoclonal gammopathy of undetermined significance (MGUS) is an age-related condition with prevalence as high as 3% in persons older than 50 years. Compared with whites, blacks have around two- and threefold higher prevalence rates of MGUS and multiple myeloma (MM), respectively. Risk of progression from MGUS to MM has been found to be very similar in whites and blacks. On average, the transformation rate to a malignant monoclonal gammopathy is 1% per year, with the mechanisms of progression likely related to bone marrow microenvironment and/or the cytokine network. Overall, the actuarial probability of progression at 25 years of follow-up is about 30%. However, when the competing causes of death are taken into account, the actual rate of progression is only 11%. The predictors of malignant transformation are the plasma cell mass (M-protein size and/or proportion of plasma cell in the bone marrow), IgA isotype, serum free light-chain ratio and 'evolving' type and ratio between phenotypically aberrant and normal bone marrow plasma cells. It is recommended to follow these patients, particularly those with high risk of progression, annually to detect MM before complications, such as renal failure or extensive skeletal, involvement occur.

Entities:  

Mesh:

Year:  2008        PMID: 18668131     DOI: 10.1038/leu.2008.203

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  27 in total

1.  Incidental finding of monoclonal gammopathy in blood donors: a follow-up study.

Authors:  Massimo La Raja; Monica Barcobello; Nicola Bet; Paolo Dolfini; Marina Florean; Federica Tomasella; Vincenzo De Angelis; Luca Mascaretti
Journal:  Blood Transfus       Date:  2012-03-28       Impact factor: 3.443

2.  Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Julieta Panero; Jorge Arbelbide; Dorotea Beatriz Fantl; Hernán García Rivello; Dana Kohan; Irma Slavutsky
Journal:  Mol Med       Date:  2010-07-14       Impact factor: 6.354

Review 3.  Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Authors:  Brendan M Weiss; W Michael Kuehl
Journal:  Expert Rev Hematol       Date:  2010-04       Impact factor: 2.929

4.  Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.

Authors:  Brendan M Weiss; Joseph Hebreo; Daniel V Cordaro; Mark J Roschewski; Thomas P Baker; Kevin C Abbott; Stephen W Olson
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

5.  Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma.

Authors:  Rishi K Wadhera; Robert A Kyle; Dirk R Larson; Angela Dispenzieri; Shaji Kumar; Hillard M Lazarus; S Vincent Rajkumar
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

6.  LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.

Authors:  Albert Gutierrez; Renee C Tschumper; Xiaosheng Wu; Tait D Shanafelt; Jeanette Eckel-Passow; Paul M Huddleston; Susan L Slager; Neil E Kay; Diane F Jelinek
Journal:  Blood       Date:  2010-07-01       Impact factor: 22.113

Review 7.  Monoclonal gammopathy of undetermined significance and smoldering myeloma: new insights into pathophysiology and epidemiology.

Authors:  Ola Landgren
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

Review 8.  Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites.

Authors:  A J Greenberg; C M Vachon; S V Rajkumar
Journal:  Leukemia       Date:  2011-12-23       Impact factor: 11.528

Review 9.  Prevalence of monoclonal gammopathy of undetermined significance: a systematic review.

Authors:  Rishi K Wadhera; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2010-08-16       Impact factor: 7.616

10.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.